GP
LGND icon

Grow Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Grow Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-220,413
Closed -$7.32M – 15
2014
Q4 		$7.32M Buy
220,413
+8,015
+4% +$261K 6.7% 5
2014
Q3 		$6.23M Buy
212,398
+8,496
+4% +$282K 5.58% 8
2014
Q2 		$7.92M Buy
203,902
+71,975
+55% +$2.92M 5.75% 5
2014
Q1 		$5.54M Sell
131,927
-188,673
-59% -$7.86M 3.65% 12
2013
Q4 		$10.5M Buy
+320,600
New +$10.4M 6.41% 3

Other funds holding LGND

William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Grow Partners's LGND Position: Q1 2015 in Review

Grow Partners sold out of Ligand Pharmaceuticals (LGND) in Q1 2015, closing a stake of 220,413 shares — an estimated $7.32M sold.

Grow Partners first reported a position in LGND in Q4 2013 and held it in 5 quarters. The position peaked at $10.5M in Q4 2013. 187 funds tracked by Wall St. Rank hold LGND as of Q1 2015.

  • Grow Partners reported no remaining Ligand Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Grow Partners sold 220,413 Ligand Pharmaceuticals shares in Q1 2015, an estimated $7.32M.
  • Grow Partners first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Grow Partners's Ligand Pharmaceuticals position peaked at $10.5M in Q4 2013.
  • 187 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2015.

Based on Grow Partners's 13F filing for Q1 2015, filed 18 May 2015.